icon
View Focus Area

Lung Cancer Biomarker Testing ECHO 2022-2023 Expansion

September 2022

-

May 2023

Understanding the Barriers and Pathways to Lung Cancer Biomarker Testing Central Hub

This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.

Didactic Presenter

Raymond Osarogiagbon, MBBS, FACP

Understanding the Barriers and Pathways to Lung Cancer Biomarker Testing Eastern Hub

This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.

Didactic Presenter

Suresh Ramalingam, MD, FASCO

Adequate Tissue for Sampling Central Hub

This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.

Didactic Presenter

Eric Flenaugh, MD, FCCP

Adequate Tissue for Sampling Eastern Hub

This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.

Didactic Presenter

Gerard Silvestri, MD, MS, FCCP

Choice of Panel, Interpretation of Results, and Next Steps - Central Hub

This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).

Didactic Presenter

Ignacio Wistuba, MD

Choice of Panel, Interpretation of Results, and Next Steps – Eastern Hub

This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).

Improving Turnaround Time – Central Hub

This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.

Didactic Presenter

Lynette Sholl, MD, FCAP

Improving Turnaround Time - Eastern Hub

This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.

Didactic Presenters

Lynette Sholl, MD, FCAP

Texas - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Arkansas- Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Louisiana - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Tennessee - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

West Virginia - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Florida - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Virginia - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

South Carolina - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Our Experts

expert-head-shot

Bruce Johnson, MD, FASCO

Chief Clinical Research Officer at Dana-Farber/Harvard Cancer Center

Past-President of the American Society of Clinical Oncology

expert-head-shot

Timothy Mullett, MD, MBA, FAC

Medical Director, Markey Cancer Center Network Development

expert-head-shot

Gerard Silvestri, MD, MS, FCCP

Hillenbrand Professor of Thoracic Oncology at Medical University of South Carolina

Immediate Past President of the American College of Chest Physicians

expert-head-shot

Suresh Ramalingam, MD, FASCO

Deputy Director, Winship Cancer Institute

Professor, Department of Hematology and Medical Oncology

Roberto C. Goizueta Distinguished Chair for Cancer Research

Director, Lung Cancer Program

expert-head-shot

Lynette Sholl, MD, FCAP

Associate Professor of Pathology

expert-head-shot

Farhood Farjah, MD, MPH, FACS

Associate Professor of Surgery

Endowed Chair in Lung Cancer Research

Associate Medical Director for the Surgical Outcomes Research Center

expert-head-shot

Robert Smith, PhD, FSBI

Senior Vice President, Cancer Screening

expert-head-shot

Pierre De Delva, MD

Section Chief of General Thoracic Surgery

Associate Program Director, Cardiothoracic Fellowship Program

expert-head-shot

Zhonglin Hao, MD, PHD

Professor of Medicine and Cancer Biology and Medical Director

expert-head-shot

Eric Flenaugh, MD, FCCP

Director of Advanced Diagnostic Interventional Pulmonary Medicine

Lung Nodule Clinic Physician Director

expert-head-shot

Raymond Osarogiagbon, MBBS, FACP

Director, Multidisciplinary Thoracic Oncology Program

expert-head-shot

Michal Senitko, MD, DAABIP

Section Chief, Interventional Pulmonology and Assistant Professor of Medicine and Surgery at the University of Mississippi Medical Center

Co-Director Lung Cancer Screening Program at UMMC Cancer Center and Research Institute

expert-head-shot

Ignacio Wistuba, MD

Division Head and interim, Division of Pathology/Lab Medicine Professor

Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine

expert-head-shot

Jhanelle E. Gray, MD

expert-head-shot

Mark Socinski, MD

expert-head-shot

Rami Manochakian, MD

expert-head-shot

Estelamari Rodriguez, MD

University of Miami Health System

expert-head-shot

Sajjad A. Bhatti, MD

University Of Arkansas for Medical Sciences

expert-head-shot

Humdum Durrani, MD

expert-head-shot

Sheena Bhalla, MD

Assistant Professor | Internal Medicine – Hematology/Oncology

expert-head-shot

Farrah Kheradmand, MD

Professor | Medicine-Pulmonary Baylor College of Medicine

expert-head-shot

Bryan Burt, MD, FACS

Professor and Chief, Division of Thoracic Surgery

Department of Surgery

 

expert-head-shot

Linda Green, MD

Pathology and Immunology

Baylor College of Medicine

expert-head-shot

Philip Edward Lammers, MD

expert-head-shot

Melissa Johnson, MD

expert-head-shot

Korey Hofmann, MPH

Program Manager

National Lung Cancer Round Table

Collected Program Resources

Lung Cancer Biomarker Testing ECHO – Texas –9-19-2022 – Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Texas – 9-19-22 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Florida –9-22-2022 – Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Arkansas –9-22-2022 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Arkansas –9-22-2022 –Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Tennessee – 9-23-2022 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Tennessee – 9-23-2022 –Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Florida –9-22-2022 – Recording

View More

Video

Financial Support Provided By

  • Sponsor Logo
  • Sponsor Logo

Get Involved

Complete the fields below to learn more about how the American Cancer Society uses the ECHO Model to fight cancer on all fronts, inquire about an upcoming ECHO, or to learn how you can join us in our mission to save lives, celebrate lives, and lead the fight for a world without cancer.

Contact Us

Involved-2

Support the American Cancer Society ECHO program with a contribution.

This Website is administered by the American Cancer Society, Inc. on behalf of the Office of Cancer Research & Implementation. Copyright © 2022 American Cancer Society ECHO American Cancer Society, Inc.

Privacy Policy